Tuberculous pericarditis with cardiac tamponade in a patient receiving adalimumab
Journal of Case Reports and Clinical Studies · 26.02.2026 · 2 (1) · 1
DOI: 10.46439/casereports.2.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Case Reports and Clinical Studies, online erschienen am 26.02.2026. Verfasst von Anastasija Zaicenko und 2 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Background
Tuberculous pericarditis is a rare manifestation of tuberculosis in developed countries and poses a significant diagnostic challenge due to its nonspecific clinical presentation. Immunocompromised individuals, particularly those receiving tumor necrosis factor-alpha (TNF-α) inhibitors, are at substantially increased risk of developing tuberculosis. Therefore, screening for tuberculosis infection and active disease is essential prior to initiating biological therapy. Case Report: A woman in her 20s with ankylosing spondylitis had negative tuberculosis screening prior to starting adalimumab therapy. After approximately one year of treatment, she presented with a dry cough, exertional dyspnea, and fever. Imaging revealed diffuse miliary pulmonary nodules, focal consolidations, hilar and mediastinal lymphadenopathy, and a large pericardial effusion. Transthoracic echocardiography confirmed cardiac tamponade. Echocardiography-guided pericardiocentesis was performed, and pericardial fluid was submitted for microbiological analysis. Disseminated tuberculosis with pericardial involvement was microbiologically confirmed by positive Xpert MTB/RIF and mycobacterial culture results from pericardial fluid, sputum, and stool specimens. The patient was transferred to a specialist unit and started on first-line antituberculous therapy combined with corticosteroids to prevent constrictive pericarditis. She demonstrated progressive clinical and radiological improvement, including complete resolution of the pericardial effusion and negative follow-up sputum microscopy, and was discharged to complete therapy with outpatient follow-up.
Conclusions
This case demonstrates that severe extrapulmonary tuberculosis, including tuberculous pericarditis complicated by life-threatening cardiac tamponade, can occur in patients receiving TNF-α inhibitors despite negative pre-treatment screening. It highlights the limitations of baseline tuberculosis testing, underscores the need for sustained clinical vigilance during biological therapy, and illustrates successful management with first-line antituberculous therapy combined with corticosteroids.
Zitieren
APA
Zaicenko, A., Kuksa, L., & Zarovska, E. (2026). Tuberculous pericarditis with cardiac tamponade in a patient receiving adalimumab. Journal of Case Reports and Clinical Studies, 2(1), 1. https://doi.org/10.46439/casereports.2.012
Vancouver
Zaicenko A, Kuksa L, Zarovska E. Tuberculous pericarditis with cardiac tamponade in a patient receiving adalimumab. Journal of Case Reports and Clinical Studies. 2026;2(1):1. doi:10.46439/casereports.2.012
BibTeX
@article{Zaicenko2026,
author = {Zaicenko, Anastasija and Kuksa, Liga and Zarovska, Evija},
title = {Tuberculous pericarditis with cardiac tamponade in a patient receiving adalimumab},
journal = {Journal of Case Reports and Clinical Studies},
year = {2026},
volume = {2},
number = {1},
pages = {1},
doi = {10.46439/casereports.2.012}
}
EUVIMED